Payahoo Laleh, Khajebishak Yaser, Asghari Jafarabadi Mohammad, Ostadrahimi Alireza
Talented Student Center, Student Research Committee, Nutrition Research Center, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran.
Student Research Committee, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran.
Adv Pharm Bull. 2018 Aug;8(3):479-487. doi: 10.15171/apb.2018.056. Epub 2018 Aug 29.
Obesity as a serious public health problem worldwide, results in the incidence of many chronic diseases. Obesity has been recognized as a chronic low-grade inflammation disorder. Altered endocannabinoid system tone is also involved in the pathogenesis of obesity. The present study aimed to investigate the effects of oleoylethanolamide supplementation on inflammatory biomarkers and oxidative stress in obese people. This randomized, double-blind, placebo-controlled clinical trial was carried out on 60 healthy obese people in 2016 in Tabriz, Iran. Eligible subjects were randomly divided into intervention (received daily, two 125 mg OEA capsules) and control groups (the same amounts of starch) and treated for 8 weeks. Blood samples (5 ml) were taken in fasting state at the baseline and at the end of the study. The concentrations of MDA and TAS were measured using a spectrophotometer. A high sensitive-C reactive protein level was measured by Immunoturbidimetry assay using the commercial kit. IL-6 and TNF-α levels were assayed by the ELISA method. The differences between groups were assessed by ANCOVA and statistical significance was determined at p<0.05. Analysis was done on 56 participants who continued intervention until the end of the study. A significant decrease in the IL-6 and TNF-α serum concentrations was observed in the intervention group (p<0.001). Changes in other variables were undetectable (p>0.05). The use of OEA as a complementary pharmacotherapy agent could be effective in improving inflammation and oxidative stress in obese people. Future studies are needed to confirm the obtained results.
肥胖作为一个全球性的严重公共卫生问题，导致了许多慢性疾病的发生。肥胖已被公认为是一种慢性低度炎症性疾病。内源性大麻素系统调节异常也参与了肥胖的发病机制。本研究旨在探讨补充油酰乙醇胺对肥胖人群炎症生物标志物和氧化应激的影响。这项随机、双盲、安慰剂对照的临床试验于2016年在伊朗大不里士对60名健康肥胖者进行。符合条件的受试者被随机分为干预组（每日服用两粒125毫克油酰乙醇胺胶囊）和对照组（等量淀粉），并接受8周治疗。在基线和研究结束时，于空腹状态采集5毫升血样。使用分光光度计测量丙二醛（MDA）和总抗氧化能力（TAS）的浓度。使用商业试剂盒通过免疫比浊法测定高敏C反应蛋白水平。采用酶联免疫吸附测定法（ELISA）检测白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）水平。通过协方差分析评估组间差异，以p<0.05确定统计学显著性。对56名持续干预至研究结束的参与者进行了分析。干预组中IL-6和TNF-α血清浓度显著降低（p<0.001）。其他变量的变化未被检测到（p>0.05）。使用油酰乙醇胺作为辅助药物治疗剂可能对改善肥胖人群的炎症和氧化应激有效。需要进一步的研究来证实所得结果。
